Clinical Trial

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
Protocol Amendment History 3 changes
notable Trial sites expanded: 26 -> 30 locations 2026-08-08
notable Enrollment increased: 87 -> 153 participants 2026-05-23
notable Sponsor changed: BeiGene -> BeOne Medicines 2026-05-23
Trial Details
NCT Number NCT06598800
Lead Sponsor BeOne Medicines
Conditions Advanced Solid Tumor
Enrollment 153 participants
Start Date 2024-10-18
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07